Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 4/4/2020
SIETES contiene 92956 citas

 1 a 20 de 94 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Healy D, Mangin D. Clinical judgments, not algorithms, are key to patient safety. BMJ 2019;367:2 de octubre. [Ref.ID 103204]
2. Cita con resumen
Pinzani V, Ladhari C. Jeux pathologiques : pas seulement les agonistes dopaminergiques !. BIP Occitanie 2019;26:octubre. [Ref.ID 103198]
3. Cita con resumen
Anónimo. FDA drops boxed warning on smoking cessation drug. DIA Daily 2016:1. [Ref.ID 101000]
4. Cita con resumen
Tan K, Petrie KJ, Faasse K, Bolland MJ, Grey A. Unhelpful information about adverse drug reactions. BMJ 2014;349:g5019. [Ref.ID 98190]
5. Cita con resumen
Kesselheim AS, Avorn J, Greene JA. Risk, responsibility, and generic drugs. N Engl J Med 2012;367:1679-81. [Ref.ID 93957]
6. Cita con resumen
Emery J, McKenzie A, Bulsara C, Holman D'Arcy. Next goal: consistency of packaging and labelling. BMJ 2010;341:64. [Ref.ID 88869]
7.Tiene citas relacionadas Cita con resumen
Garattini S, Bertele V. Europe's opportunity to open up drug regulation. BMJ 2010;340:842-3. [Ref.ID 88339]
8. Cita con resumen
Anónimo. Avoid percentages when describing risks of side effects to patients. BMJ 2009;339:362. [Ref.ID 86496]
Quinzler R, Gasse C, Schneider A, Kaufmann-Kolle P, Szecsenyi J, Haefeli WE. The frequency of inappropriate tablet splitting in primary care. Eur J Clin Pharmacol 2006;62:1065-73. [Ref.ID 78697]
10. Cita con resumen
Anónimo. US medicine group seeks to cut medication errors. Scrip 2006;3179:17. [Ref.ID 77698]
Anónimo. Conduite et médicaments. avant tout, examiner les effets du traitement. Prescrire 2005;26:16. [Ref.ID 75765]
Bergk V, Haefeli WE, Gasse C, Brenner H, Martin-Facklam M. Information deficits in the summary of product characteristics preclude an optimal management of drug interactions: a comparison with evidence from the literature. Eur J Clin Pharmacol 2005;61:327-35. [Ref.ID 74486]
13. Cita con resumen
San Miguel MT, Martínez JA, Vargas E. Food-drug interactions in the summary of product characteristics of proprietary medicinal produts. Eur J Clin Pharmacol 2005;61:77-83. [Ref.ID 73695]
15.Tiene citas relacionadas Cita con resumen
Topol EJ, Falk GW. A coxib a day won't keep the doctor away. Lancet 2004;364:639-40. [Ref.ID 71272]
16. Cita con resumen
Anónimo. CPMP backs COX-2s with stronger risk warnings. Scrip 2003;2905:22. [Ref.ID 68262]
Anónimo. Ribavirin. Package inserts revised for co-administration with interferon alfa-2b. WHO Pharmaceuticals Newsletter 2003;1:2. [Ref.ID 65216]
18. Cita con resumen
Anónimo. FDA & Roche faulted for weak Accutane controls. Scrip 2002;2808:13. [Ref.ID 64469]
19. Cita con resumen
Anónimo. FDA panel wants stronger acetaminophen warnings. Scrip 2002;2784:18. [Ref.ID 63565]
20. Cita con resumen
Anónimo. Nefazodone: rare cases of liver failure. United States of America. WHO Drug Information 2002;16:28. [Ref.ID 62068]
Seleccionar todas
 1 a 20 de 94 siguiente >>